GSK-923295: Small-Molecule CENP-E Inhibitor for Mitotic Arrest in Cancer Research

Executive Summary: GSK-923295 is a highly potent small-molecule inhibitor that targets the mitotic kinesin motor protein CENP-E, with a K_i of 3.2 nM, leading to mitotic arrest and cell cycle delay in tumor cells (APExBIO). CENP-E is essential for chromosome alignment and metaphase-anaphase transition, integrating spindle checkpoint signaling through kinetochore-microtubule interactions (Walsh et al., 2026). GSK-923295 stabilizes the ATP-bound state of CENP-E, suppressing microtubule-stimulated ATPase activity and mimicking RNAi knockdown phenotypes. In vitro, it demonstrates broad-spectrum tumor cell growth inhibition, and in vivo, it achieves dose-dependent tumor regression in colon cancer xenografts. The compound is supplied as a solid, highly soluble in DMSO and ethanol, and is intended for research use only (APExBIO).

Biological Rationale

Mitosis ensures accurate segregation of duplicated chromosomes between daughter cells. The mitotic spindle, composed of microtubules, connects to the centromere via kinetochores. CENP-E (Centromere-associated protein E) is a kinesin motor protein localized at the kinetochore, required for chromosome congression and proper alignment at the metaphase plate (GSK-923295: A Next-Generation CENP-E Inhibitor for Cancer...). Loss or inhibition of CENP-E disrupts tension sensing and spindle checkpoint fidelity, resulting in mitotic arrest or abnormal chromosome segregation (Walsh et al., 2026). CTCF, a chromatin looping factor, also maintains centromere function but acts upstream or parallel to CENP-E recruitment and activity. Mitotic checkpoint integrity is thus contingent on both structural proteins (e.g., CTCF, cohesin) and dynamic motors like CENP-E. GSK-923295, by directly inhibiting CENP-E, provides a tool for dissecting these checkpoint pathways and studying cell cycle regulation in cancer models. This article extends the mechanistic focus of Targeting Mitotic Kinesins for Cancer Therapy... by adding quantitative benchmarks and usage parameters for GSK-923295.

Mechanism of Action of GSK-923295

GSK-923295 is a reversible, ATP-competitive inhibitor of CENP-E's microtubule-stimulated ATPase activity. It binds the motor domain of CENP-E, stabilizing the ATP-bound conformation and slowing ADP and inorganic phosphate release. This inhibition prevents CENP-E-driven movement along microtubules, blocking congression of chromosomes to the metaphase plate (APExBIO). The cellular phenotype of GSK-923295 treatment mirrors RNAi-mediated CENP-E depletion, with increased mitotic index, delayed metaphase-anaphase transition, and abnormal spindle morphology. Inhibition is highly potent (K_i = 3.2 nM), and specificity for CENP-E has been validated biochemically and by phenocopying genetic knockdown (GSK-923295: A Next-Generation CENP-E Inhibitor for Cancer...). In contrast to spindle poisons (e.g., taxanes), GSK-923295 does not broadly destabilize microtubules but acts through targeted checkpoint disruption. This clarifies and updates the molecular perspective offered in Harnessing Mitotic Checkpoint Control: GSK-923295 and the... by detailing the biochemical sequence of inhibition.

Evidence & Benchmarks

• GSK-923295 exhibits a mean GI₅₀ of 253 nM (median 32 nM) across 237 tumor cell lines in vitro, indicating broad-spectrum antiproliferative activity (APExBIO).
• 125 mg/kg intraperitoneal dosing in mice with Colo205 colon tumor xenografts induced dose-dependent tumor regression, with both partial and complete responses observed (APExBIO).
• Inhibition of CENP-E with GSK-923295 leads to increased mitotic index and accumulation of cells with unaligned chromosomes, as confirmed by immunofluorescence imaging (Walsh et al., 2026).
• GSK-923295 stabilizes the ATP-bound form of CENP-E and slows release of ADP and Pi, as demonstrated in enzymatic ATPase assays (APExBIO).
• Loss of CENP-E function results in phenotypes overlapping those observed after CTCF depletion, including metaphase plate disorganization and mitotic failure (Walsh et al., 2026).

Applications, Limits & Misconceptions

Applications: GSK-923295 is optimized for studies of mitotic checkpoint signaling, chromosome alignment, and cell cycle regulation in cancer research. It enables targeted disruption of the microtubule motor protein pathway and robust assessment of checkpoint fidelity. The compound is suitable for both in vitro and in vivo models, with validated use in tumor xenograft assays and cell proliferation studies (APExBIO).

Limits: The inhibitor is not broadly cytotoxic to non-dividing cells and does not directly affect global microtubule stability. It is insoluble in water, requiring DMSO or ethanol (ultrasonication recommended) for stock preparation. GSK-923295 is for research use only; it is not indicated for diagnostic or clinical applications. Storage at -20°C is essential to maintain stability, and solutions should be used promptly to avoid degradation.

Common Pitfalls or Misconceptions

• Misconception: GSK-923295 is a general microtubule poison.
  Fact: It selectively inhibits CENP-E motor activity without destabilizing microtubules.
• Misconception: The compound is suitable for water-based formulations.
  Fact: GSK-923295 is insoluble in water; use DMSO or ethanol with ultrasonication for dissolution.
• Misconception: It can be used clinically.
  Fact: GSK-923295 is strictly for research use; not approved for medical or diagnostic purposes.
• Pitfall: Improper storage leads to compound degradation.
  Advice: Store at -20°C and avoid repeated freeze-thaw cycles.
• Pitfall: Assuming effects are due to global checkpoint collapse.
  Advice: Phenotypes are specific to CENP-E inhibition and should be distinguished from upstream centromere or cohesin defects.

Workflow Integration & Parameters

For in vitro use, GSK-923295 is typically dissolved at ≥29.6 mg/mL in DMSO or ≥14.87 mg/mL in ethanol (with ultrasonication), then diluted into culture medium. Recommended working concentrations range from 10–500 nM, depending on cell line sensitivity and assay duration. For in vivo studies, validated protocols use 125 mg/kg intraperitoneal dosing in mice (APExBIO). All solutions must be freshly prepared to preserve activity. Experimental readouts include mitotic index, chromosome alignment, and apoptosis quantification. For detailed workflows and troubleshooting, see the related guide, GSK-923295: A Next-Generation CENP-E Inhibitor for Cancer...—this article adds context on storage, solubility, and benchmarking.

Conclusion & Outlook

GSK-923295 is a rigorously validated, small-molecule CENP-E inhibitor that enables precise dissection of the mitotic kinesin motor protein pathway in cancer research. Its efficacy in cell cycle arrest, chromosome alignment studies, and tumor regression models supports its use as a gold-standard tool for checkpoint biology. APExBIO supplies GSK-923295 (SKU: a3450) for research use, with comprehensive usage data and benchmarks. Future research may expand its role in combination therapies and in elucidating centromere maintenance dynamics, especially in light of emerging findings on CTCF and cohesin (Walsh et al., 2026).